PARP Inhibitor

Corcept Therapeutics presented Phase 3 ROSELLA trial data at ESMO 2025, showing relacorilant plus nab-paclitaxel significantly improved progression-free and overall survival in platinum-resistant ovarian cancer patients, including those progressing on PARP inhibitors. The combination also demonstrated a favorable safety profile. Corcept is expanding the Phase 2 BELLA trial to include platinum-sensitive ovarian and endometrial cancer arms, with initial results expected in late 2026. The FDA has granted relacorilant priority review for platinum-resistant ovarian cancer with a PDUFA date of July 11, 2026.